Convatec upgrades after strong quarter in wound business
Convatec has raised its guidance for organic revenue growth to 6-7.5% from 5-6.5% previously, which is somewhat better than analysts’ expectations.
By MarketWire
British Convatec, which competes with Coloplast, has upgraded its guidance for 2023 after a strong second quarter, during which the company’s the wound care business was particularly strong.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Coloplast acquisition doubles in value in just one year
For subscribers
